# Safety and Immunogenicity of the Candidate Vaccine MVA-MERS-S_DF-1 Against MERS

> **NCT04119440** · PHASE1 · COMPLETED · sponsor: **Universitätsklinikum Hamburg-Eppendorf** · enrollment: 145 (actual)

## Conditions studied

- MERS (Middle East Respiratory Syndrome)

## Interventions

- **BIOLOGICAL:** MVA-MERS-S_DF1 - Low Dose
- **BIOLOGICAL:** MVA-MERS-S_DF1 - High Dose
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04119440
- **Lead sponsor:** Universitätsklinikum Hamburg-Eppendorf
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-16
- **Primary completion:** 2022-11-28
- **Final completion:** 2024-11-06
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2025-04-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04119440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04119440, "Safety and Immunogenicity of the Candidate Vaccine MVA-MERS-S_DF-1 Against MERS". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04119440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*